All News Elevation Oncology, Inc.

Equities

ELEV

US28623U1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
3.74 ^USD	+3.60%		+5.65%	+596.46%

May. 14	Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target	MT
May. 02	Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target	May. 14	MT
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution and Cash Liquidating Dividend Amount of $15.10 per Share of Common Stock	May. 13	AQ
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements	May. 03	AQ
Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Elevation Oncology, Inc. Announces Management Changes	Apr. 05	CI
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements	Mar. 07	AQ
Wedbush Raises Elevation Oncology's PT to $8 From $5, Continues to See 'Intriguing' Opportunity in Shares; Keeps Outperform Rating	Mar. 07	MT
Elevation Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors	Mar. 04	CI
JMP Securities Starts Elevation Oncology' With Market Outperform Rating	Mar. 01	MT
Elevation Oncology to Participate in Upcoming Investor Conferences	Feb. 29	AQ
Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm	Feb. 29	PR
Elevation Oncology Expands Phase 1 Study of Potential Solid Tumor Treatment	Feb. 22	MT
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan	Feb. 22	CI
HC Wainwright Adjusts Elevation Oncology Price Target to $6 From $1.50, Maintains Buy Rating	Feb. 20	MT
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma	Feb. 14	AQ
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors	Jan. 23	AQ
Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee	Jan. 22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Elevation Oncology, Inc.

Equities

ELEV

US28623U1016

All News

Filters